Dass Serena Diane, Cheah Phaik-Leng, Ong Diana Bee-Lan, Teoh Kean-Hooi, Looi Lai-Meng
University of Malaya, Faculty of Medicine, Department of Pathology, 50603 Kuala Lumpur, Malaysia.
Malays J Pathol. 2015 Apr;37(1):19-24.
Loss of E-cadherin, a 120 kDA transmembrane glycoprotein responsible for cell-cell adhesion, is one of the hallmarks of epithelial-mesenchymal-transition (EMT). E-cadherin expression was immunohistochemically studied in 94 histopathologically re-confirmed colorectal carcinomas (CRC) using a monoclonal antibody to E-cadherin (Dako: Clone NCH-38) on a Ventana Benchmark XT automated system. Each case was assessed for E-cadherin immunopositivity at two separate locations viz the tumour centre (TC) as well as the infiltrating front (IF). Expression was semiquantitated for proportion of immunopositive malignant cells as 0 (negative), 1 (1-25% staining), 2 (26-50% staining), 3 (51-75% staining) and 4 (>75% staining) and staining intensity: 0 (negative), 1 (weak), 2 (moderate) and 3 (strong). The final histoscore of E-cadherin immunopositivity was arbitrarily computed as proportion of immunopositivity multiplied by staining intensity of the malignant cells. E-cadherin histoscores were significantly lower at the IF (4.5±2.5) compared with TC (10.7±2.4). Furthermore, the histoscores were significantly reduced at the IF of 49 TNM III+IV tumours (3.6±2.5) compared with 45 II+III CRC (5.4±2.2). Reduction of E-cadherin expression was also noted in the 23 high grade (TC=8.6±3.2; IF=2.6±2.3) compared with 71 low grade tumours (TC=11.4±1.5; IF=5.1±2.3). E-cadherin is downregulated at the infiltrating front of CRC, possibly marking for EMT at this location. The downregulation is further enhanced amongst late stage and high grade tumours compared with earlier stage and low grade tumours; findings which are similar to that noted in CRC of other populations.
E-钙黏蛋白是一种负责细胞间黏附的120 kDa跨膜糖蛋白,其缺失是上皮-间质转化(EMT)的标志之一。在Ventana Benchmark XT自动系统上,使用抗E-钙黏蛋白的单克隆抗体(Dako:克隆NCH-38),对94例经组织病理学再次确认的结直肠癌(CRC)进行E-钙黏蛋白表达的免疫组织化学研究。在肿瘤中心(TC)和浸润前沿(IF)这两个不同位置对每个病例进行E-钙黏蛋白免疫阳性评估。根据免疫阳性恶性细胞的比例将表达进行半定量:0(阴性)、1(1-25%染色)、2(26-50%染色)、3(51-75%染色)和4(>75%染色),以及染色强度:0(阴性)、1(弱)、2(中度)和3(强)。E-钙黏蛋白免疫阳性的最终组织学评分通过免疫阳性比例乘以恶性细胞的染色强度来任意计算。与TC(10.7±2.4)相比,E-钙黏蛋白组织学评分在IF处(4.5±2.5)显著更低。此外,与45例II+III期CRC(5.4±2.2)相比,49例TNM III+IV期肿瘤在IF处的组织学评分显著降低(3.6±2.5)。与71例低级别肿瘤(TC=11.4±1.5;IF=5.1±2.3)相比,在23例高级别肿瘤中也观察到E-钙黏蛋白表达降低(TC=8.6±3.2;IF=2.6±2.3)。E-钙黏蛋白在CRC的浸润前沿下调,可能在此位置标志着EMT。与早期和低级别肿瘤相比,晚期和高级别肿瘤中的下调进一步增强;这些发现与其他人群CRC中的情况相似。